You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of TaurusTrioTM TAVR System Released
2025.05.24
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of TaurusTrioTM ···

Highlights: The pivotal clinical trial enrolled 116 symptomatic patients wi···
EuroPCR 2025 30-Day Follow-Up Results from Initial Feasibility Study of Highlife® TSMVR System Released
2025.05.23
EuroPCR 2025 30-Day Follow-Up Results from Initial Feasibility Study of Hig···

Highlights: 1. The reported results were derived from a single-center feasi···
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of GeminiOne® TEER System Released
2025.05.23
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of GeminiOne® TE···

Highlights: The pivotal trial enrolled 130 patients (including 10 roll-in p···
ONE-YEAR FOLLOW-UP RESULTS OF THE REGISTRATION  TRIAL OF TAURUSTRIO™ TAV SYSTEM PRESENTED AT CHINA  VALVE (HANGZHOU) 2025
2025.04.21
ONE-YEAR FOLLOW-UP RESULTS OF THE REGISTRATION TRIAL OF TAURUSTRIO™ TAV SY···

On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunf···
REGISTRATION APPLICATION FOR TaurusTrio™ TAV  SYSTEM ACCEPTED BY THE NMPA
2025.04.15
REGISTRATION APPLICATION FOR TaurusTrio™ TAV SYSTEM ACCEPTED BY THE NMPA

On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted ···
HighLife granted US FDA Breakthrough Device Designation for its TMVR solution
2025.04.08
HighLife granted US FDA Breakthrough Device Designation for its TMVR soluti···

We are thrilled to congratulate our incredible partner HighLife Medical on ···
SUCCESSFULLY COMPLETION OF THE FIRST TWO IMPLANTSWITH THE TrilogyTM TRANSCATHETER HEART VALVE SYSTEMIN TAIWAN, CHINA
2025.03.05
SUCCESSFULLY COMPLETION OF THE FIRST TWO IMPLANTSWITH THE TrilogyTM TRANSCA···

This announcement is made by Peijia Medical Limited (the “ Company”, together wi···
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY  COMPLETED THE FIRST NATIONAL IMPLANTATION  OF THE TAURUSMAXTM TRANSCATHETER AORTIC  VALVE REPLACEMENT SYSTEM
2025.02.10
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY COMPLETED THE FIRST NATIONAL IMPLAN···

The team led by Academician Ge Junbo from Zhongshan Hospitalaffiliated with Fuda···
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SUCCESSFULLYCOMPLETED THE FIRST FEE-BASED COMPASSIONATE USETREATMENT IN HONG KONG
2024.11.28
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SUCCESSFULLYCOMPLETED THE FIRST FEE-B···

In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-···
PCR London Valves : HighLife® TSMVR SYSTEM (HighLife®) ANNOUNCED THE 1- YEAR CLINICAL FOLLOW-UP RESULTS OF THE FIRST 45 PATIENTS FROM A FEASIBILITY STUDY FOR THE FIRST TIME, LAYING A SOLID EVIDENCE-BASED FOUNDATION FOR FUTURE CE APPROVAL
2024.11.26
PCR London Valves : HighLife® TSMVR SYSTEM (HighLife®) ANNOUNCED THE 1- YEA···

According to the clinical results, HighLife® achieved atechnical success rate of···
THE LATEST PROGRESS IN THE FIM STUDY OF MonarQ™ IN EUROPE AND AMERICA WAS ANNOUNCED AT TCT 2024
2024.11.06
THE LATEST PROGRESS IN THE FIM STUDY OF MonarQ™ IN EUROPE AND AMERICA WAS A···

Since the first implantation in November 2023, a total of 9 patients have been ···
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® FEASIBILITY STUDY WERE ANNOUNCED AT TCT 2024
2024.11.05
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® FEASIBILITY STUDY WERE ANNOUNCED AT···

Two-year clinical data of the HighLife® TSMVR technology's feasibility tria···
Home < 12345··· > Last
Top